Lyme Disease Testing Market By Testing Method (Standard Two-Tier Testing [STTT], Modified Two-Tier Testing [MTTT], Single-Tier and Direct-Detection Testing, Specialized Neurologic Testing); By Technology (Enzyme Immunoassay [EIA/ELISA], Western Immunoblot, Polymerase Chain Reaction [PCR], Antigen Detection, ImmunoBlot, Antibody Index Testing, Emerging Molecular and Biomarker Platforms); By Sample Type (Blood and Serum, Cerebrospinal Fluid, Urine, Interstitial Fluid, Other Clinical Specimens); By End User (Hospital Laboratories, Independent and Reference Laboratories, Diagnostic Centers, Specialty Clinics, Academic and Research Institutes, Point-of-Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Lyme Disease Testing Market: The Diagnostic Window Shapes Commercial Demand

The Global Lyme Disease Testing Market was valued at USD 0.59 billion in 2025 and is projected to reach USD 0.91 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research.

 

Approved Lyme diagnostics are primarily FDA-cleared two-step blood antibody tests that detect IgM and IgG responses to Borrelia burgdorferi using enzyme immunoassays with confirmatory immunoblot or a modified two-tier approach using two sequential EIAs, both of which measure immune response rather than the bacteria itself. In development, key innovations include Pfizer/Valneva’s VLA15 OspA vaccine in Phase 3 trials to prevent infection by inducing antibodies that kill Borrelia within feeding ticks, EC Pocket Lyme as a rapid point-of-care molecular detection device, and TP-05 as an oral prophylactic aimed at preventing tick-borne transmission.
 

Lyme disease is diagnosed and treated in about 476,000 people each year in the U.S., with most cases underreported in official counts.

It is most common in the Northeast, mid-Atlantic, and upper Midwest.Globally, it is found in about 80 countries, especially across North America, Europe, and parts of Asia. Western Europe reports over 200,000 cases annually.

Some estimates suggest up to 14% of the world’s population has been exposed at some point, though true global totals are uncertain. Deaths from Lyme disease are very rare.

 

The Test Is Available Before the Answer Is Reliable

Lyme disease testing is commercially established, but its performance changes sharply with the timing of sample collection. Standard two-tier serology has only 30% to 40% sensitivity during early localized infection, when antibodies are still developing. Some studies place sensitivity near 35% in patients with early erythema migrans, while false-negative rates during the first few weeks can reach 50% to 60% or more, depending on the patient group and testing time.

CDC guidance warns that serologic assays may remain falsely negative for the first four to six weeks after infection. A negative result soon after a tick bite therefore does not always end the diagnostic process. Patients with continuing symptoms may return for another consultation and a repeat blood draw. CDC reporting guidance recommends collecting another sample after 7 to 14 days when recent infection is strongly suspected, while Public Health Ontario advises follow-up specimens two to four weeks apart in selected cases. Repeat sampling creates additional testing volume but also exposes the main weakness of antibody-dependent products.

Testing is not always required when the clinical presentation is clear. A patient with a typical expanding erythema migrans rash and credible exposure in a Lyme-endemic area can be diagnosed and treated without waiting for serology. Early testing may provide little value in such cases because measurable antibodies may not yet be present. The testing market is therefore strongest among patients without the characteristic rash, those with unclear symptoms, later-stage manifestations, and cases requiring confirmation before specialist referral.

 

Two Tiers Protect Accuracy but Add Work

The CDC recommends either standard two-tier testing, known as STTT, or modified two-tier testing, known as MTTT. Under STTT, a laboratory first runs an enzyme immunoassay or ELISA. A negative first-tier result generally ends the process. A positive or equivocal result is followed by an IgM or IgG Western immunoblot. The final interpretation depends on the combined result rather than either test alone.

MTTT replaces the Western blot with a second enzyme immunoassay. This allows laboratories to retain a two-stage confirmation process while using technologies that are easier to automate and interpret. The FDA cleared the first four assays for this approach in 2019 after determining that the alternative method performed at least as well as the traditional testing pathway. Public Health Ontario now uses two ELISA stages and no longer offers immunoblotting for routine Lyme serology.

A 2025 real-world study reported that adults tested through MTTT had 1.88 times the odds of receiving a positive result compared with adults tested through STTT. The result supports greater detection under routine laboratory conditions, although a higher positive rate does not by itself prove that every additional result represents an active infection. Laboratories still need clinical history, symptom duration, and exposure information to interpret the finding correctly.

MTTT carries a clear commercial advantage for high-volume laboratories. Running two automated immunoassays can reduce manual blot interpretation, simplify staff training, and produce more consistent reporting. Public Health Ontario performs MTTT daily during the summer and autumn peak season, with non-reactive results generally available within five days and reactive results within seven days. Its seasonal schedule shows how testing capacity is adjusted to tick activity rather than maintained at a uniform level throughout the year.

 

Blood Holds 62.4% Because the Workflow Is Already Built Around It

Blood samples represented an estimated 62.4% of the Lyme disease testing market in 2025. Their lead reflects more than clinical familiarity. The recommended two-tier process can be completed from the same blood specimen, allowing laboratories to reflex a positive first-stage result into a second assay without recalling the patient immediately.

Serum testing also fits existing immunoassay equipment used by hospital and reference laboratories for many infectious and autoimmune conditions. Test manufacturers can therefore sell Lyme assays into laboratories that already have instruments, sample-preparation procedures, and trained staff. This lowers adoption barriers compared with tests that require dedicated molecular systems or uncommon specimen types.

Consumer-access services are widening the blood-testing channel. Labcorp currently offers a USD 99 patient-initiated Lyme antibody test collected at one of its laboratories, with reported results generally available within one to two days after the sample arrives. The service still uses the CDC-recommended two-step approach, and a healthcare professional must authorize the order. Such offerings improve access but do not remove the need for clinical interpretation because a positive result may reflect past exposure rather than current disease.

Blood will remain the principal specimen category until direct-detection technologies demonstrate reliable performance during the earliest stage of infection. PCR has not displaced serology in routine blood testing because the number of circulating Borrelia organisms is often too low for consistent detection. Antibody assays therefore retain the largest volume even though they cannot fully answer whether an infection is active.

 

Accuracy Improves as the Disease Advances

The commercial value of established two-tier tests increases in disseminated and later-stage disease. Sensitivity rises from approximately 30%–40% in early infection to 70%–100% in disseminated manifestations, including neurologic disease and Lyme arthritis. Standard two-tier specificity remains above 95% across disease stages, making the method useful for confirming clinically suspected cases once an antibody response has developed.

Higher late-stage accuracy does not eliminate interpretation problems. IgG and, in some situations, IgM antibodies can remain detectable for months or years after successful treatment. Serology cannot reliably distinguish a resolved infection from an active one and should not be used to measure treatment response. A previously infected patient may continue to test positive during an unrelated illness, while reinfection can be difficult to separate from past exposure using antibody results alone.

Cross-reactivity creates another source of unnecessary follow-up. Initial immunoassays can react in patients with relapsing fever, syphilis, rheumatoid arthritis, Epstein-Barr virus infection, and other immune conditions. The second tier protects specificity by requiring confirmation, but it also generates additional laboratory work whenever the first test is positive or unclear.

These limitations divide the market into two commercial needs. Established serology addresses exposure and immune response with high later-stage accuracy. Emerging assays are trying to detect active infection earlier, distinguish current disease from previous exposure, and reduce dependence on paired samples.

 

Neurologic Cases Create a Smaller but Higher-Value Testing Path

Suspected Lyme neuroborreliosis requires more specialized testing than routine blood serology. Laboratories may assess paired serum and cerebrospinal fluid samples to calculate an intrathecal anti-Borrelia antibody index. The index identifies antibodies produced within the central nervous system rather than antibodies that have passively entered the cerebrospinal fluid from the bloodstream.

Published performance varies by patient group and disease stage, but the antibody index has shown sensitivity of approximately 80% to 86% in established cases, with high specificity. A normal result does not completely exclude neuroborreliosis, particularly when testing occurs early. Clinical guidelines therefore continue to place serum antibody testing and cerebrospinal-fluid findings within a broader neurologic assessment.

Direct detection performs less consistently in cerebrospinal fluid. Reported CSF PCR sensitivity ranges from approximately 5% to 38%, with many reviews placing the typical range near 10% to 30%. Specificity can approach 99% when contamination and assay controls are well managed. Culture has similarly poor sensitivity, generally around 10% to 30% or lower, and is too slow and unreliable for routine clinical use.

Although neurologic testing represents less volume than blood serology, it generates greater revenue per case through lumbar puncture, paired-sample analysis, antibody-index calculation, and specialist interpretation. Its growth depends on better standardization rather than large-scale screening.

 

Surveillance Turns Geography and Season into Laboratory Volume

Testing demand is concentrated in the northeastern, mid-Atlantic, and upper-Midwestern United States. Fifteen high-incidence jurisdictions account for most reported American cases. Laboratories serving these regions experience seasonal peaks that affect reagent inventory, turnaround times, and staffing requirements.

The European market is smaller in value but more complex in assay design. Different Borrelia species circulate across Europe, increasing the importance of assays that detect a broader antigen range. Public Health Ontario uses a separate screening route when European Lyme disease is suspected and requires travel history to direct the specimen through the appropriate pathway. This creates opportunities for multi-antigen assays but makes global product standardization more difficult.

England reported 1,581 laboratory-confirmed cases in 2024, down 5.2% from 1,667 cases in 2023. Acute cases declined 16.7%, from 1,151 to 959, although the UK Health Security Agency continues to regard Lyme disease as an important vector-borne infection. Updated surveillance placed England’s laboratory-confirmed rate at 1.64 per 100,000 people in 2024, rising to 1.99 per 100,000 in 2025. Annual movement can reflect weather, outdoor exposure, reporting patterns, and testing activity, so laboratories cannot plan capacity from a single year’s case count.

 

Public Funding Is Targeting the Early-Diagnosis Gap

Public investment is shifting development toward tests that can identify active infection before conventional antibodies become detectable. The LymeX Diagnostics Prize awarded USD 5.1 million during its first three phases. Phase 4 offers up to USD 3 million, with another potential USD 3 million linked to teams achieving FDA clearance. The program is designed to move products beyond academic prototypes and into regulatory-ready development.

HHS renewed the LymeX partnership in December 2025 through a USD 10 million initiative focused on earlier and more accurate detection, including the use of artificial intelligence. In May 2026, HHS announced a wider Lyme disease plan that included up to USD 2.5 million in innovation challenges alongside surveillance, prevention, and research measures.

FDA-supported researchers are also developing a common LymeX diagnostic data structure. Standardized clinical and laboratory data could help developers compare assay performance across early disease, later manifestations, and persistent post-treatment symptoms. Better datasets would reduce one of the main development risks: testing a new assay against patient groups that are too small or poorly defined to support regulatory review.

 

New Tests Must Clear More Than a Scientific Hurdle

The 2025 Hybrid Lyme ELISA study reported sensitivity above 90% for patients with erythema migrans, with sufficient reported specificity to support investigation as a single-tier test. The assay is commercially relevant because replacing two tests with one could reduce turnaround time and laboratory handling. It remains a development-stage technology and will require broader prospective validation before it can change routine testing.

Researchers at Dartmouth Hitchcock Medical Center also presented three droplet-digital PCR assays in 2025 that detected as few as five to ten Borrelia cells in analytical testing. Direct detection could shorten the antibody window, but conference-stage performance must still translate into reproducible clinical sensitivity, practical sample preparation, and an affordable laboratory workflow.

ID-FISH Technology received FDA clearance for its iDart Lyme IgG ImmunoBlot in 2024 and its IgM ImmunoBlot in 2025. The kits contain 31 and 26 antigen bands, respectively, and were positioned for sale to laboratories seeking to add or update Lyme testing. These clearances show that improved immunoblot products can still find a place even as MTTT gains adoption.

T2 Biosystems illustrates the financial risk facing diagnostic developers. Its direct-from-blood T2Lyme Panel received FDA Breakthrough Device designation and remained in the company’s pipeline in January 2025. T2 Biosystems terminated substantially all employees in February 2025, ceased operations, and announced the completion of its wind-down in February 2026. The program’s scientific potential was not enough to overcome the company’s financing and operating constraints.

 

Company Strategies Split Between Scale and Early Detection

The competitive landscape is divided between large reference laboratories, specialty diagnostic companies, and development-stage firms targeting active infection. Quest Diagnostics and Labcorp hold an advantage through nationwide sample collection, established payer relationships, and automated serology systems. Quest offers both standard two-tier and modified two-tier testing, while Labcorp uses FDA-cleared assays in its modified two-tier profile. These companies are positioned to benefit from the gradual shift toward MTTT because the approach fits high-volume immunoassay systems and reduces dependence on manually interpreted Western blots.

Quest Diagnostics Expands Dominance in High-Volume Lyme Testing as Modified Two-Tier Adoption Accelerates
Quest’s test menu includes standard antibody testing with reflex immunoblot and modified testing with a second immunoassay. Labcorp’s MTTT profile first measures total antibodies and automatically reflexes reactive samples to separate IgG and IgM assays. Their commercial strength comes from integrating Lyme testing into existing infectious-disease services rather than relying on a dedicated Lyme platform. Both laboratories can also combine Lyme assays with babesiosis, anaplasmosis, ehrlichiosis, and other tick-borne infections, supporting broader panels when symptoms do not indicate a single pathogen.

ID-FISH Technology and IGeneX Push High-Resolution Immunoblotting as FDA-Cleared Band Expansion Reshapes Specialty Testing
ID-FISH Technology and IGeneX are competing through broader antigen coverage and specialization in tick-borne disease testing. ID-FISH received FDA clearance for its iDart Lyme IgG ImmunoBlot in August 2024 and its IgM ImmunoBlot in June 2025. The IgG and IgM kits contain 31 and 26 antigen bands, respectively. ID-FISH planned to sell the kits to laboratories adding Lyme testing or updating existing menus, while IGeneX uses the underlying ImmunoBlot technology within its specialty laboratory services. This strategy extends the technology beyond a single reference laboratory and creates revenue from both diagnostic services and distributed test kits.

LymeX Prize Finalists Race Toward First-Generation Direct Detection as Blood, Urine, and Molecular Platforms Compete for FDA Pathway
Early-detection developers are pursuing targets that differ from established antibody assays. Seven teams advanced to Phase 4 of the LymeX Diagnostics Prize in 2025. BlueArc Biosciences is developing a blood test for direct detection of Borrelia burgdorferi. HelixBind is working on a direct-from-blood molecular assay, while Galaxy Diagnostics is developing a urine-based antigen test. Other teams are evaluating glycan biomarkers, epigenetic host responses, nucleic-acid enrichment, and blood or urine biomarkers. The program is moving these assays toward clinical validation and FDA review rather than funding early laboratory research alone.

En Carta Diagnostics Gains Breakthrough Status for EC Pocket Lyme as Near-Bite Molecular Testing Challenges Traditional Serology Timelines
En Carta Diagnostics is developing EC Pocket Lyme as a single-use molecular cassette intended to detect Borrelia in interstitial fluid collected near a tick bite or erythema migrans lesion. The test received FDA Breakthrough Device designation in 2026. Its potential advantage is testing close to the suspected infection site without waiting several weeks for a measurable antibody response. Commercial adoption will depend on whether clinical studies reproduce this early-detection performance across different patients, tick exposures, and Borrelia strains.

Prevention developers could also influence future testing patterns. Pfizer and Valneva reported that their investigational Lyme vaccine, PF-07307405 or LB6V, achieved more than 70% efficacy in the Phase 3 VALOR trial, and Pfizer plans regulatory submissions. Wider preventive use could reduce infections among vaccinated populations, but vaccine-related antibodies may require laboratories and assay manufacturers to establish clear interpretation rules. Tarsus Pharmaceuticals is separately developing TP-05 as an oral prophylactic that kills attached ticks before disease transmission. These products are not part of the testing market, but they may change which patients are tested and how exposure history is assessed.

 

Reimbursement and Evidence Will Decide Which Tests Scale

Medicare pays most clinical diagnostic laboratory tests through the Clinical Laboratory Fee Schedule, which is based on private-payer rate data. CMS confirmed that no CLFS payment reduction applies in 2026, while annual reductions from 2027 through 2029 may be capped at 15%. A listed billing code does not guarantee coverage, so new Lyme assays must show clinical utility rather than analytical performance alone.

The regulatory position of laboratory-developed tests also changed materially. A federal district court vacated the FDA’s 2024 LDT final rule in March 2025, and FDA restored the earlier regulatory wording in September 2025. Specialty laboratories retain more operating flexibility than the phased rule would have allowed, but FDA-cleared kits still carry an advantage when developers seek broad hospital adoption, distribution partnerships, and consistent payer recognition.

The market’s largest constraint remains the gap between the time a patient needs an answer and the time conventional serology performs best. Blood testing will continue to dominate because it is standardized, reimbursable, and compatible with automated laboratory systems. The strongest strategic opportunity lies with tests that improve early-stage sensitivity without sacrificing the greater than 95% specificity achieved by established two-tier protocols. Products that can also distinguish active infection from past antibody exposure would address the market’s most persistent clinical and commercial weakness.

 

Analyst Perspective: Workflow Fit Will Matter More Than Novelty

The Lyme Disease Testing Market is expected to grow at a 6.4% CAGR from 2026–2032, driven by higher awareness, repeat testing during early infection, and wider use of modified two-tier testing. Growth is steady rather than rapid because many clear rash cases are treated without lab testing, limiting unnecessary diagnostics.

Blood-based testing will continue to dominate with a 62.4% market share, supported by existing lab infrastructure, reimbursement systems, and fully automated workflows. Tests that run on standard lab equipment are more likely to scale than those requiring new platforms.

Modified two-tier testing is the main near-term shift, replacing Western blot with automated immunoassays. This improves speed and consistency for large labs like Quest Diagnostics and Labcorp, while keeping serology central to Lyme diagnosis.

Direct detection tests represent the biggest long-term opportunity but remain difficult to commercialize. They must detect very low bacterial levels early in infection while maintaining >95% specificity and proving clinical value for treatment decisions.

Overall, established labs such as Quest and Labcorp are expected to retain routine testing volume, while companies like ID-FISH, IGeneX, and LymeX participants target niche or early-infection gaps. Success will depend more on reimbursement, regulatory approval, and workflow compatibility than on test complexity.

Preventive products like vaccines may reduce some infections but are unlikely to reduce testing demand. Instead, they may increase diagnostic needs by complicating interpretation of past exposure and vaccination status.

 

Lyme Disease Testing Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.59 Billion
Revenue Forecast in 2032	USD 0.91 Billion
Overall Growth Rate	CAGR of 6.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Testing Method, By Technology, By Sample Type, By End User, By Geography
By Testing Method	Standard Two-Tier Testing [STTT], Modified Two-Tier Testing [MTTT], Single-Tier and Direct-Detection Testing, Specialized Neurologic Testing
By Technology	Enzyme Immunoassay [EIA/ELISA], Western Immunoblot, Polymerase Chain Reaction [PCR], Antigen Detection, ImmunoBlot, Antibody Index Testing, Other Emerging Molecular and Biomarker Platforms
By Sample Type	Blood and Serum, Cerebrospinal Fluid, Urine, Interstitial Fluid, Other Clinical Specimens
By End User	Hospital Laboratories, Independent and Reference Laboratories, Diagnostic Centers, Specialty Clinics, Academic and Research Institutes, Point-of-Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Sweden, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnostic demand in endemic regions, repeat testing during the early antibody-negative window, growing adoption of automated modified two-tier testing, expansion of direct-detection and point-of-care platforms, and stronger public funding for early Lyme disease diagnosis
Customization Option	Available upon request